小剂量地西他滨治疗高危骨髓增生异常综合征的效果  

Effect of low-dose desitabine on high-risk myelodysplastic syndrome

作　　者：李振波 陈丽梅[2] 陆诚 LI Zhen-bo;CHEN Li-mei;LU Cheng(Baoji Hi-tech People's Hospital,Baoji 721000;the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710000;Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,China)

机构地区：[1]宝鸡高新人民医院,陕西宝鸡721000 [2]西安交通大学第一附属医院,陕西西安710000 [3]宝鸡市中医医院,陕西宝鸡721000

出　　处：《临床医学研究与实践》2020年第14期8-9,共2页Clinical Research and Practice

基　　金：陕西省社会发展科技攻关项目(No.2009K18-01)。

摘　　要：目的探讨小剂量地西他滨治疗高危骨髓增生异常综合征的效果及对预后的影响。方法将我院收治的64例高危骨髓增生异常综合征患者按照随机数字表法分为对照组和研究组,各32例。对照组应用常规联合化疗治疗,研究组应用小剂量地西他滨治疗。比较两组的治疗效果。结果研究组血液系统不良反应发生率、2、3年生存率以及生存时间均优于对照组(P<0.05)。结论采用小剂量地西他滨治疗DNMT3和TET2基因型高危骨髓增生异常综合征,可以减少患者治疗期间不良反应,并延长生存时间。Objective To investigate the effect of low-dose desitabine in the treatment of high-risk myelodysplastic syndrome and its influence on prognosis. Methods Sixty-four patients with high-risk myelodysplastic syndrome admitted in our hospital were divided into control group and study group according to the random number table method, with 32 cases in each group. The control group was treated with conventional combined chemotherapy, while the study group was treated with low-dose desitabine. The therapeutic effects of the two groups were compared. Results The incidences of adverse reactions in the blood system, 2-year and 3-year survival rates and survival time of the study group were better than those of the control group(P <0.05). Conclusion Low-dose desitabine therapy for DNMT3 and TET2 genotype high-risk myelodysplastic syndrome can reduce adverse reactions during treatment, and prolong the survival time of patients.

关 键 词：骨髓增生异常综合征 地西他滨 生存情况 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R733.71[医药卫生—内科学]